Lithium Ion

Lithium Ion

SCHEMBL4783272

CN(C)CCN(C)c1n[nH]c2cc(C(=O)[O-])ccc12.[Li+]

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.38
KIT P10721 2/20 0.38
FGFR2 P21802 1/20 0.38
PARP1 P09874 2/20 0.36
MAPK8 P45983 2/20 0.35
MAPK10 P53779 2/20 0.35
MAPK14 Q16539 2/20 0.35
CSNK2A1 P68400 1/20 0.35
HIPK2 Q9H2X6 1/20 0.35
ABL1 P00519 2/20 0.35
BCR P11274 2/20 0.35
EGFR P00533 5/20 0.35
MAPK1 P28482 1/20 0.35
NTRK1 P04629 1/20 0.34
FLT3 P36888 1/20 0.33
CHEK1 O14757 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4782714 0.87 MAP2K4 (0.41) FGFR1KITFGFR2MAPK8MAPK10
SCHEMBL4783277 0.86 MAP2K4 (0.40) FGFR1KITFGFR2MAPK8MAPK10
SCHEMBL4785231 0.76 POLB (0.50) MAPK8MAPK10MAPK14MAPK1
SCHEMBL4785918 0.74 LSS (0.54) MAPK10MAPK14MAPK1
SCHEMBL4784771 0.74 LMNA (0.52) MAPK8MAPK10MAPK14MAPK1
SCHEMBL4782765 0.72 ALDH1A1 (0.51) KITMAPK8MAPK10MAPK14MAPK1
SCHEMBL4783573 0.68 GSK3B (0.44) EGFRNTRK1
Lithium Ion SCHEMBL4783900 0.65 MAPK1 (0.45) FGFR1KITMAPK10ABL1BCR
SCHEMBL1041712 0.64 MAP2K4 (0.43) MAPK1
Lithium Ion SCHEMBL19328996 0.61 PARP1 (0.44) PARP1HIPK2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
WO-2008061109-A2 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS MCHR1, MCHR2, MC1R FGFR1 568/4885KIT 282/4885FGFR2 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.